血脑屏障通透化合物库
目录号：L4700
811个独特的血脑屏障通透化合物集合，具有生物活性，可用于神经系统研究。
| 规格 |
|---|
| 预溶于DMSO或水 |
| 100uL/well |
| 询价获取超大折扣! |
您可以选择特定规格、位置的分子
定制您的化合物库
客户使用Selleck的血脑屏障通透化合物库发表文献299篇
- Cell, 2020 181(7):1518-1532.e14
- Signal Transduct Target Ther, 2020 4;5:20.
- Cell Metab, 2019 7;29(5):1166-1181.e6.
- Cancer Discov, 2019 9(7):910-925
- Cancer Discov, 2018 8(4):498-515
- Nature, 2017 546(7659):533-538
- Cancer Discov, 2015 5(2):154-67.
- Nat Med, 2014 20(8):954-60
- Cancer Cell, 2021 S1535-6108(21)00383-4
- Chem Soc Rev, 2021 10.1039/d0cs01065k
- Cancer Discov, 2021 candisc.0872.2020
- Nat Methods, 2022 19(7):803-811
- Nat Biomed Eng, 2022 10.1038/s41551-022-00863-9
- Blood, 2022 blood.2022015414
- Cancer Discov, 2021 candisc.0930.2020
- Nat Immunol, 2024 25(10):1884-1899
- Nat Biomed Eng, 2024 10.1038/s41551-024-01273-9
- Nat Commun, 2021 12(1):1117
- J Am Chem Soc, 2021 143(13):4979-4992
- Nat Chem Biol, 2021 10.1038/s41589-021-00751-4
- Acta Pharm Sin B, 2021 11(1):181-202
- Clin Cancer Res, 2021 clincanres.4037.2020
- J Exp Clin Cancer Res, 2021 40(1):90
- Proc Natl Acad Sci U S A, 2021 118(13)e2009620118
- Cell Death Dis, 2021 12(2):183
- Cell Rep, 2021 35(1):108940
- Cell Rep, 2021 35(1):108959
- Clin Epigenetics, 2021 13(1):54
- Am J Cancer Res, 2021 11(1):215-235
- ACS Infect Dis, 2021 10.1021/acsinfecdis.0c00853
- J Biol Chem, 2021 jbc.RA120.016477
- ACS Omega, 2021 6(36):23399-23411
- Sci Adv, 2021 7(10)eabe7853
- Nat Commun, 2020 14;11(1):1792.
- Nucleic Acids Res, 2020 48(20):11566-11576
- J Allergy Clin Immunol, 2020 21;S0091-6749(20)30259-1.
- Cancer Res, 2020 15;80(4):832-842.
- EBioMedicine, 2020 60:102988
- Cancer Lett, 2020 469:195-206
- Cell Death Dis, 2020 2;11(3):158.
- Cell Death Dis, 2020 11(9):724
- Cell Rep, 2020 32(1):107845
- Cell Chem Biol, 2020 20;27(2):197-205.e6.
- Cell Chem Biol, 2020 16;27(1):94-104.e5.
- Stem Cell Reports, 2020 14(3):478-492
- Mol Ther Oncolytics, 2020 30;17:169-179.
- Int J Mol Sci, 2020 18;21(8):2825.
- Cancers (Basel), 2020 12(6)E1418
- Antimicrob Agents Chemother, 2020 4;AAC.02523-19.
- J Biol Chem, 2020 27;jbc.RA120.012981.
- Carcinogenesis, 2020 41(7):993-1004
- Sci Rep, 2020 24;10(1):5318.
- Toxicol Sci, 2020 1;174(2):218-240.
- Breast Cancer Res Treat, 2020 179(2):337-347.
- PLoS One, 2020 15(1):e0228189
- PLoS One, 2020 15(5):e0233672
- PLoS One, 2020 15(5):e0233089
- bioRxiv, 2020 2020.04.20.051581
- bioRxiv, 2020 doi:10.1101/2020.05.26.117770
- Sarcoma, 2020 2020:6312480
- ACS Pharmacol Transl Sci, 2020 3(6):1278-1292
- J Med Virol, 2019 91(8):1440-1447.
- Genome Biol, 2019 20(1):253
- Cancer Immunol Res, 2019 7(9):1523-1534
- Cell Rep, 2019 5;26(6):1544-1556.e8.
- Cell Chem Biol, 2019 21;26(2):235-243.e5.
- Acta Pharmacol Sin, 2019 10.1038/s41401-019-0246-4
- Neuropsychopharmacology, 2019 10.1038/s41386-018-0266-7
- Breast Cancer Res, 2019 21(1):37
- Drug Discov Today, 2019 24(2):390-402
- Anal Chem, 2019 91(8):4995-5003
- J Med Chem, 2019 62(21):9824-9836
- Cancer Gene Ther, 2019 10.1038/s41417-019-0127-5
- Cancers (Basel), 2019 30;11(2):156.
- Bioengineered, 2019 10(1):98-107
- Cell Signal, 2019 67:109508
- mSphere, 2019 4(3)e00047-19
- Molecules, 2019 24(20)E3798
- Stem Cells Int, 2019 2019:3435901
- Neurobiol Aging, 2019 76:24-34
- Biochem J, 2019 476(15):2209-2219
- Int J Parasitol Drugs Drug Resist, 2019 10:28-37.
- Breast Cancer Res Treat, 2019 10.1007/s10549-019-05504-5
- Virology, 2019 541:41-51
- Kaohsiung J Med Sci, 2019 10.1002/kjm2.12051
- Cancer Manag Res, 2019 11:8391-8405
- Sci Adv, 2019 5(6):eaav9784
- bioRxiv, 2019 doi:10.1101/748129
- Curr Protoc Chem Biol, 2019 11(2):e64
- Nat Commun, 2018 9(1):1655
- Cancer Res, 2018 78(15):4344-4359
- Cancer Res, 2018 78(20):5731-5740
- EBioMedicine, 2018 28:80-89.
- Cell Rep, 2018 22(5):1185-1199
- Elife, 2018 7e35136
- Cancer Sci, 2018 109(4):1220-1229
- J Cell Physiol, 2018 233(1):422-433
- Oncotarget, 2018 9(57):31018-31031
- Oncotarget, 2018 9(40):26086-26095
- Oncotarget, 2018 9(32):22571-22585
- Antimicrob Agents Chemother, 2018 62(12)e01302-18
- Sci Rep, 2018 8(1):13106
- Sci Rep, 2018 21;8(1):14178.
- Sci Rep, 2018 8(1):12046
- PLoS Negl Trop Dis, 2018 12(3):e0006326
- Biochem Biophys Res Commun, 2018 495(1):1468-1475
- SLAS Discov, 2018 23(2):164-173
- Methods Mol Biol, 2018 1795:203-221.
- Methods Mol Biol, 2018 1765:333-347
- Nat Commun, 2017 17;8:16078.
- Proc Natl Acad Sci U S A, 2017 114(36):E7554-E7563
- Cell Rep, 2017 20(4):999-1015
- Anal Chem, 2017 89(12):6678-6685
- J Med Chem, 2017 60(7):2973-2982
- Lab Chip, 2017 31;17(3):511-520.
- Mol Cancer Ther, 2017 16(12):2656-2667
- Oncotarget, 2017 8(43):73745-73756
- Oncotarget, 2017 8(32):53154-53167
- Antimicrob Agents Chemother, 2017 62(1)
- Sci Rep, 2017 7(1):14416
- PLoS One, 2017 5;12(1):e0169407.
- Parasit Vectors, 2017 10(1):323
- SLAS Discov, 2017 22(5):507-515
- SLAS Discov, 2017 22(5):484-493
- SLAS Discov, 2017 22(9):1120-1130
- Biol Pharm Bull, 2017 40(8):1289-1298.
- Parasitol Res, 2017 116(10):2619-2626.
- Methods Cell Biol, 2017 138:651-679
- PhD School in Cell Biology and Development, 2017 1-76
- Pharmacol Res, 2016 113(Pt A):216-227
- J Invest Dermatol, 2016 136(10):2041-2048
- Database (Oxford), 2016 7;2016:baw041.
- Oncotarget, 2016 7(48):79637-79653
- ACS Infect Dis, 2016 2(3):180-186
- J Cyst Fibros, 2016 15(3):285-94
- Biogerontology, 2016 17(5-6):907-920.
- PLoS Genet, 2016 12(9):e1006279
- Sensors (Basel), 2016 16(3)
- PLoS One, 2016 11(2):e0149848
- PLoS One, 2016 11(6):e0157497
- Curr Protoc Toxicol, 2016 69:9.10.1-9.10.26
- Biosens Bioelectron, 2015 68:699-704
- Genome Biol, 2015 19;16(1):127.
- Clin Cancer Res, 2015 21(5):1172-82
- Cancer Res, 2015 75(24):5341-54
- Mol Cancer Ther, 2015 14(5):1213-23
- Oncotarget, 2015 6(3):1531-43
- Oncotarget, 2015 6(34):35247-62
- Cell Cycle, 2015 14(1):109-22
- PLoS One, 2015 10(11):e0142655
- PLoS One, 2015 10(2):e0117246
- PLoS One, 2015 10(2):e0116688
- Head Neck, 2015 37(12):1722-32
- Assay Drug Dev Technol, 2015 13(8):456-65
- Oncotarget, 2014 5(15):6512-25
- Mol Cancer Res, 2014 12(5):703-13
- PLoS One, 2014 9(9):e106784
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Curr Protoc Chem Biol, 2014 4:177-191
- Oncogenesis, 2013 2:e69
- Nat Commun, 2021 12(1):4360
- Nat Commun, 2021 12(1):5220
- Nat Commun, 2021 12(1):5111
- Cancer Commun (Lond), 2021 10.1002/cac2.12189
- Mol Cell, 2021 S1097-2765(21)00314-2
- Adv Sci (Weinh), 2021 8(11):e2003558
- Clin Cancer Res, 2021 clincanres.5026.2020
- Clin Cancer Res, 2021 clincanres.0464.2021
- PLoS Biol, 2021 19(5):e3001221
- Cancer Lett, 2021 514:12-29
- Brief Bioinform, 2021 bbab113
- Cell Rep, 2021 35(4):109024
- Cell Chem Biol, 2021 S2451-9456(21)00434-7
- EMBO Rep, 2021 e51781
- Stem Cell Res Ther, 2021 12(1):151
- J Med Chem, 2021 10.1021/acs.jmedchem.1c00367
- Eur J Med Chem, 2021 223:113576
- Hemasphere, 2021 5(7):e602
- Mol Oncol, 2021 10.1002/1878-0261.13083
- J Invest Dermatol, 2021 S0022-202X(21)01672-9
- Comput Struct Biotechnol J, 2021 19:3674-3681
- Commun Biol, 2021 4(1):573
- Mol Cancer Ther, 2021 molcanther.MCT-20-0666-E.2020
- Mol Cancer Ther, 2021 molcanther.MCT-20-0377-A.2020
- Int J Mol Sci, 2021 22(4)1750
- Int J Mol Sci, 2021 22(15)8320
- Front Cell Dev Biol, 2021 9:673374
- Cancers (Basel), 2021 13(3)576
- Transl Oncol, 2021 14(9):101147
- Transl Oncol, 2021 14(12):101230
- Methods, 2021 S1046-2023(21)00015-3
- Neoplasia, 2021 23(9):929-938
- Viruses, 2021 13(7)1255
- Front Oncol, 2021 11:735820
- Sci Rep, 2021 11(1):4390
- Sci Rep, 2021 11(1):14062
- Sci Rep, 2021 11(1):19343
- Sci Rep, 2021 11(1):19443
- AAPS J, 2021 23(2):35
- J Immunol, 2021 ji2000969
- Clin Transl Allergy, 2021 11(5):e12045
- J Biomol Struct Dyn, 2021 1-17
- Hum Cell, 2021 10.1007/s13577-021-00497-0
- Hum Cell, 2021 10.1007/s13577-021-00497-0
- Glycobiology, 2021 cwab048
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- J Gastroenterol Hepatol, 2021 10.1111/jgh.15490
- Biochem J, 2021 BCJ20210257
- Biochem J, 2021 478(13):2481-2497
- Pathogens, 2021 10(2)253
- Epigenetics, 2021 1-12
- Cell Tissue Res, 2021 10.1007/s00441-021-03496-7
- Cancer Cytopathol, 2021 10.1002/cncy.22448
- Biochem Biophys Res Commun, 2021 560:1-6
- J Biosci Bioeng, 2021 S1389-1723(21)00178-X
- FEBS Open Bio, 2021 11(5):1452-1464
- In Vivo, 2021 35(2):761-777
- Tohoku J Exp Med, 2021 254(1):17-23
- J Toxicol Sci, 2021 46(4):167-176
- Biol Pharm Bull, 2021 10.1248/bpb.b21-00531
- STAR Protoc, 2021 2(1):100345
- FASEB Bioadv, 2021 3(5):334-355
- Genes Cancer, 2021 12:12-24
- NAR Cancer, 2021 3(2):zcab018
- Vaccines (Basel), 2020 8(1)E72
- Antimicrob Agents Chemother, 2019 AAC.01470-19
- Biomed Opt Express, 2018 9(5):2214-2228
- Oncotarget, 2017 8(28):45088-45104
- Assay Drug Dev Technol, 2017 15(5):198-209
- Proc Natl Acad Sci U S A, 2014 111(51):E5564-73
- Carcinogenesis, 2014 35(9):1968-76
- Mol Biol Cell, 2013 24(10):1559-73
- Sci Transl Med, 2022 14(652):eabl5654
- Nat Commun, 2022 13(1):2725
- Nat Commun, 2022 13(1):2169
- Nat Commun, 2022 13(1):2572
- Adv Sci (Weinh), 2022 9(22):e2201785
- Nucleic Acids Res, 2022 50(13):7420-7435
- Clin Cancer Res, 2022 clincanres.0100.2022
- Clin Transl Med, 2022 12(7):e961
- Haematologica, 2022 107(1): 77–85
- Cells, 2022 11(7)1091
- Biosensors (Basel), 2022 12(2)96
- Front Cell Neurosci, 2022 16:852245
- ACS Chem Neurosci, 2022 13(10):1505-1516
- Neoplasia, 2022 27:100784
- Immunol Lett, 2022 244:28-39
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Infect Drug Resist, 2022 15:295-306
- Exp Cell Res, 2022 413(2):113079
- J Neurophysiol, 2022 127(2):405-411
- J Am Chem Soc, 2021 10.1021/jacs.1c06167
- Cell Death Differ, 2021 1-8
- EMBO Mol Med, 2021 e14608
- Front Immunol, 2021 12:680611
- Eur J Med Chem, 2021 228:114022
- Cancer Sci, 2021 112(11):4641-4654
- Int J Mol Sci, 2021 22(22)12223
- Transl Oncol, 2021 15(1):101260
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 34(6):1911-1918
- Cannabis Cannabinoid Res, 2021 10.1089/can.2021.0132
- PLoS One, 2021 16(10):e0259129
- Genes (Basel), 2021 12(5)742
- Mol Biol Rep, 2021 10.1007/s11033-021-06797-w
- Nat Commun, 2023 14(1):3830
- Anal Chem, 2023 95(20):7985-7992.
- Cancers (Basel), 2023 15(5)1526
- Br J Cancer, 2022 126(12):1815-1823.
- J Med Virol, 2022 10.1002/jmv.27951
- Cell Death Differ, 2022 10.1038/s41418-022-01064-2
- J Exp Clin Cancer Res, 2022 41(1):86
- BMC Med, 2022 20(1):175
- Oncogene, 2022 10.1038/s41388-022-02328-4
- Cancer Metab, 2022 10(1):6
- Front Pharmacol, 2022 13:861295
- Endocrinology, 2022 163(8)bqac090
- Hum Cell, 2022 10.1007/s13577-022-00701-9
- Biochem Biophys Res Commun, 2022 632:181-188
- J Mol Model, 2022 28(6):153
- Cold Spring Harb Protoc, 2022 10.1101/pdb.prot098269
- Front Microbiol, 2021 12:651403
- OUR Archive, 2022
- J Exp Clin Cancer Res, 2023 42(1):100
- J Infect Dis, 2023 228(5):591-603
- Elife, 2023 12RP84926
- Nat Commun, 2024 15(1):5379
- bioRxiv, 2024 2024.07.13.603377
- Heliyon, 2024 10(13):e34033
- J Virol, 2024 98(7):e0041323
- Exp Mol Med, 2024 10.1038/s12276-024-01298-9
- Sci Adv, 2024 10(37):eadp4408
- Biochem Biophys Res Commun, 2024 730:150393
- bioRxiv, 2024 2023.04.19.537364
- Mol Oncol, 2024 10.1002/1878-0261.13725
- Int Immunopharmacol, 2024 141:112810
- Eur J Pharmacol, 2024 983:177000
- Proc Natl Acad Sci U S A, 2022 119(49):e2208458119
- ACS Omega, 2021 6(38):24432-24443
血脑屏障通透化合物库目录
详细信息
| 配制 | 740个化合物预溶于10mM DMSO，44个化合物预溶于10mM水，24个化合物预溶于2mM DMSO，3个化合物预溶于2mM水。 | ||
| 容器 | 铝箔热封的96深孔板 | ||
| 储存条件 (自收到货起) |
1年 | -20°C | 溶于DMSO |
| 2年 | -80°C | 溶于DMSO | |
| 发货 | 干冰或蓝冰物流 | ||
描述及优势
•811个独特的血脑屏障通透化合物集合，适用于神经系统研究
•针对5-HT受体，DHFR，COX，RAAS，AChR等靶点
•某些化合物已获得FDA批准
•结构多样，具有药用活性，可透过细胞
•提供丰富的文档信息，包括结构，IC50和客户评论
•验证NMR和HPLC以确保最高纯度
